Quick Answer
Kairos Pharma, LTD. reported Diluted EPS of $0.30 per share (loss) for fiscal year 2025.
Kairos Pharma, LTD. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.30 | -30.4% |
| 2024 | -$0.23 | -35.3% |
| 2023 | -$0.17 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.07 | +30.0% | +12.5% |
| June 30, 2025 | -$0.08 | -300.0% | +0.0% |
| March 31, 2025 | -$0.08 | -166.7% | +20.0% |
| September 30, 2024 | -$0.10 | -233.3% | -400.0% |
| June 30, 2024 | -$0.02 | — | +33.3% |
| March 31, 2024 | -$0.03 | — | +0.0% |
| September 30, 2023 | -$0.03 | — | — |
- Kairos Pharma, LTD. showed a decrease of -30.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Kairos Pharma, LTD.’s diluted eps has declined by 76.5% (from $0.17 per share (loss) to $0.30 per share (loss)).
- The most recent figure is from Kairos Pharma, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: